Management of Vaginal and Vulvar Symptoms in Postmenopausal Women

First-Line Non-Hormonal Treatment

The American College of Obstetricians and Gynecologists recommends applying vaginal moisturizers 3-5 times per week to the vagina, vaginal opening, and external vulva for symptom relief in postmenopausal women 2
Polycarbophil-based products, such as Replens, reduce vaginal dryness by 64% and dyspareunia by 60% in postmenopausal women 2
Topical vitamin D or E may provide additional symptom relief for vaginal dryness and discomfort in postmenopausal women 1, 2
Water-based or silicone-based lubricants are recommended for immediate relief during intercourse in postmenopausal women 1, 2, 3
Pelvic floor physical therapy improves sexual pain, arousal, lubrication, orgasm, and satisfaction in postmenopausal women 1, 2
Vaginal dilators help with pain during sexual activity and increase vaginal accommodation in postmenopausal women with vaginismus or vaginal stenosis 1, 2
Topical lidocaine applied to the vulvar vestibule before penetration reduces dyspareunia in postmenopausal women 1, 2

Vaginal estrogen is the most effective treatment for vaginal dryness, itching, discomfort, and painful intercourse in postmenopausal women 1, 2
Low-dose vaginal estrogen formulations minimize systemic absorption and are recommended for postmenopausal women with vaginal atrophy 2
Optimal symptom improvement with vaginal estrogen typically takes 6-12 weeks of consistent use in postmenopausal women 2
The National Comprehensive Cancer Network recommends vaginal estrogen as a second-line treatment for vaginal dryness and dyspareunia in postmenopausal women 1, 2

The American Society of Clinical Oncology recommends that non-hormonal options be tried first for at least 4-6 weeks in breast cancer survivors before considering hormonal treatment 2
Low-dose vaginal estrogen can be considered after thorough discussion of risks and benefits in breast cancer survivors who have not responded to non-hormonal treatments 1, 2
Vaginal DHEA is specifically recommended for aromatase inhibitor users who haven't responded to non-hormonal treatments 1, 2
Estriol-containing preparations may be preferable for women on aromatase inhibitors, as estriol is a weaker estrogen that cannot be converted to estradiol 1, 2

A large cohort study of nearly 50,000 breast cancer patients followed for up to 20 years showed no increased risk of breast cancer-specific mortality with vaginal estrogen use 2
Vaginal estrogen does not increase risk of stroke, deep venous thrombosis, or coronary heart disease in postmenopausal women 2
The US Preventive Services Task Force recommendation against systemic hormone therapy for chronic disease prevention does not apply to vaginal estrogen for symptomatic vaginal atrophy 2